The effect of almonds on vitamin E status and cardiovascular risk factors in Korean adults: a randomized clinical trial

Abstract

PurposeAlmonds have shown to beneficially modify some cardiovascular risk factors in clinical trials conducted in diverse ethnic populations but this relationship has never been tested in Koreans. Thus, we tested the impact of almonds consumed as a snack within the context of a typical Korean diet on cardiovascular risk factors.MethodsWe conducted a randomized, crossover trial in a free-living setting with a 2-week run-in period, two 4-week intervention phases, and a 2-week washout period between interventions. Eighty four overweight/obese participants (11 M/73 F; 52.4 ± 0.6 year; 25.4 ± 0.22 kg/m2) consumed either 56 g of almonds or isocaloric cookies daily for 4 weeks.ResultsMean % daily energy intake at baseline was 64.8, 21.3, and 14.9% from carbohydrate, fat, and protein, respectively. The addition of 56 g of almonds daily decreased carbohydrate energy to 55.0%, increased fat to 32.0%, and maintained protein at 14.7%. Consuming the almonds increased intake of MUFA by 192.3%, PUFA by 84.5%, vitamin E by 102.7%, and dietary fiber by 11.8% and decreased % energy from carbohydrate by 14.1%. Total caloric intake was increased by the almonds, but body weight, waist circumference, and body composition were not affected. Almonds in overweight and obese Korean adults decreased TC, LDL-C, and non-HDL-C by 5.5, 4.6, and 6.4%, respectively, compared to the cookie control (P ≤ 0.05). Almonds increased plasma α-tocopherol by 8.5% (P ≤ 0.05) from the baseline and tended to increase its value as compared to cookies (P = 0.055). Neither the almonds nor cookies altered plasma protein carbonyls, MDA or oxLDL. Of serum inflammatory markers, IL-10 was decreased by almond intake (P ≤ 0.05), and ICAM-1, IL-1β, and IL-6 tended to be lower with almonds, compared to the cookies.ConclusionsAlmonds at 56 g/day consumed as a snack favorably modified the Korean diet by increasing MUFA, PUFA, vitamin E, and dietary fiber intake and decreasing % energy intake from carbohydrate. Almonds also enhanced plasma α-tocopherol status and serum TC and LDL-C in overweight and obese Koreans. Thus, including almonds in typical Korean diets as a snack can help healthy overweight/obese individuals improve nutritional status and reduce their risk for CVD.Electronic supplementary materialThe online version of this article (doi:10.1007/s00394-017-1480-5) contains supplementary material, which is available to authorized users.

Effects of Consuming Almonds on Insulin Sensitivity and Other Cardiometabolic Health Markers in Adults With Prediabetes

“…No effect of almond intake was observed on markers of inflammation, which is consistent with the results of a 2017 meta-analysis assessing the effect of nut intake on endothelial function and inflammation (53). While some studies have shown a modest effect of almond consumption to reduce inflammatory markers (54)(55)(56), others have failed to show an effect (22,57). Last, in contrast to a previous RCT that found that 6 weeks of almond intake (10 g/d almonds soaked overnight prior to consumption) by subjects with coronary artery disease resulted in a significant reduction in serum uric acid levels (24), there was no effect on uric acid level in the present trial.…”

Nuts and Cardio-Metabolic Disease: A Review of Meta-Analyses

“…A meta-analysis [77] of 56 intervention studies (55 publications) [95,96,99,100,101,102,103,104,105,110,111,121,122,124,125,126,127,128,129,132,133,134,135,136,137,138,139,140,146,147,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175] showed a significant reduction in body weight (WMD = −0.22 kg; 95% CI −0.40, −0.04; I 2 = 75%). Significant reductions in waist circumference (−0.51 cm; 95% CI −0.95, −0.07; I 2 = 82%) and BMI (−0.16 kg/m 2 ; 95% CI −0.31, −0.01; I 2 = 76%) have been shown in a data from 23 intervention studies (22 publications) [95,99,105,107,125,…”

Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases

“…The degradation product D-α-tocopheryl succinate might assist the liver retention of BBR via the inhibition of P-gp efflux and cytochrome P450 (CYP450) elimination 25 . Moreover, degradation product D-α-tocopheryl, an antioxidant, might possess a synergistic effect with BBR in treating CMD 26 . Enhanced anti-CMD effects were expected at low-dose BBR application.…”